EXPERIENCE OF USE OF ITOPRIDE FOR THE TREATMENT OF ENT-MANIFESTATIONS OF LARYNGOPHARYNGEAL REFLUX


Cite item

Full Text

Abstract

Laryngopharyngeal reflux (LPR) is closely associated with gastroesophageal reflux disease and involves reflux of gastric material in laryngopharynx with appropriate clinical manifestations. The authors have assessed the effectiveness of two-week course of therapy with prokinetic itopride (Ganaton) in the treatment of otorhinolaryngologic manifestations of LPR in 20 patients. Administration of itopride led to a decrease in subjective complaints of patients and reduction of severity of laryngoscopic signs as redness and swelling of the mucous membrane of arytenoid cartilages. This observation allows to recommend the use of Ganaton in the combined treatment of LPR manifestations.

References

  1. Al Sabbagh G, Wo JM. Supraesophageal manifestations of gastroesophageal reflux disease. Semin Gastrointest Dis 1999;10:113-19.
  2. Koufman JA, Aviv JE, Casiano RR, at al. Laryngopharyngeal reflux: Position statement of the Committee on Speech, Voice, and Swallowing Disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg 2002;127:32-5.
  3. Bailey BJ, Johnson JT. Head&Neck Surgery-Otolaryngology. Lippincott Williams & Wilkins 2006.
  4. Toohill RJ, Kuhn JC. Role of refluxed acid in pathogenesis of laryngeal disorders. Am J Med 1997;103:100-6.
  5. Ulualp SO, Toohill RJ. Laryngopharyngeal reflux: state of the art diagnosis and treatment. Otolaryngol Clin North Am 2000;33:785-801.
  6. Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med 2004;164(14):1482-88.
  7. Tutuian R, Castell DO. Diagnosis of laryngopharyngeal reflux. Curr Opin Otolaryngol Head Neck Surg 2004;12(3):174-79.
  8. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease: a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991;101:1-78.
  9. Koufman JA, Belafsky PC, Bach KK, et al. Prevalence of esophagitis in patients with pH-documented laryngopharyngeal reflux. Laryngoscope 2002:112:1606-09.
  10. Wiener GJ, Koufman JA, Wu WC, et al. Chronic hoarseness secondary to gastroesophageal reflux disease: documentation with 24-h ambulatory pH monitoring. Am J Gastroenterol 1989;84:12.
  11. Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). Laryngoscope 2001;111: 1313-17.
  12. Vaezi MF, Hicks DM, Abelson TI, et al. Laryngeal signs and symptoms and gastroesophageal reflux disease: a critical assessment of cause and effect association. Clin Gastroenterol Hepatol 2003;1:333-44.
  13. Steward D, Wilson K, Kelly D, et al. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: A randomized placebo control trial. Otolaryngol Head Neck Surg 2004;13:342-50.
  14. Westcott CJ, Hopkins MB, Bach KK, et al. Fundoplication for laryngopharyngeal reflux. J Am Coll Surg 2004;199(1):23-30.
  15. Харкевич Д.А. Фармакология. М., 2006.
  16. Gupta S. Comparative study of prokinetic drugs. JK Science 2004;6(2):106-108.
  17. Rudolph CD, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001;23:1 [PMID: 11525610].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies